Cowen downgraded Constellation Pharmaceuticals from Outperform to Market Perform
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
4/A - CONSTELLATION PHARMACEUTICALS INC (0001434418) (Issuer)
4 - CONSTELLATION PHARMACEUTICALS INC (0001434418) (Issuer)
4 - CONSTELLATION PHARMACEUTICALS INC (0001434418) (Issuer)
RBC Capital Mkts downgraded Constellation Pharmaceuticals from Outperform to Sector Perform and set a new price target of $34.00 from $50.00 previously
Jefferies downgraded Constellation from Buy to Hold and set a new price target of $34.00 from $53.00 previously
Truist Securities downgraded Constellation from Buy to Hold and set a new price target of $34.00 from $50.00 previously
15-12B - CONSTELLATION PHARMACEUTICALS INC (0001434418) (Filer)
EFFECT - CONSTELLATION PHARMACEUTICALS INC (0001434418) (Filer)
S-8 POS - CONSTELLATION PHARMACEUTICALS INC (0001434418) (Filer)
Company Announces Successful Completion of Tender Offer Moves Forward with Strategic Funding Partnership with Royalty PharmaPLANEGG / MUNICH, GERMANY / ACCESSWIRE / July 15, 2021 / MorphoSys AG ((FSE:MOR, NASDAQ:MOR) ("MorphoSys") today announced the successful completion of its previously announced cash tender offer for all outstanding shares of Constellation Pharmaceuticals, Inc. (NASDAQ:CNST) ("Constellation") for $34.00 per share, net to the seller in cash, without interest and subject to any applicable withholding of taxes. The tender offer expired at one minute after 11:59 p.m. New York City Time, on July 14, 2021.Approximately 42,811,957 shares of Constellation were validly tendered,
MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / July 1, 2021 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) ("MorphoSys") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), for its tender offer for Constellation Pharmaceuticals, Inc., (NASDAQ:CNST) ("Constellation").The expiration of the HSR waiting period satisfies one of the conditions to the tender offer, which is scheduled to expire at one minute past 11:59 p.m. New York City Time, on July 14, 2021, unless extended in accordance with the terms of the merger agreement by and among Constellation, MorphoSys and MorphoSys Development Inc. ("Purchaser"). The tender
Translational data support the disease-modifying potential of pelabresibCentral pathology review confirmed bone marrow fibrosis improvements observed with pelabresib treatment Impact of pelabresib treatment observed across a wide range of myelofibrosis patient subgroups CAMBRIDGE, Mass., June 11, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that three posters relating to the MANIFEST clinical trial of pelabresib (CPI-0610) in myelofibrosis (MF) were published online in association with the European Hematology Association
MUNICH, GERMANY and CAMBRIDGE, MA / ACCESSWIRE / June 2, 2021 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) ("MorphoSys"), announces today that it has entered into a definitive agreement with Constellation Pharmaceuticals, Inc. (NASDAQ:CNST) ("Constellation") whereby MorphoSys will acquire Constellation for $34.00 per share in cash, which represents a total equity value of $1.7 billion. The transaction has been unanimously approved by the Management Board (Vorstand) and the Supervisory Board (Aufsichtsrat) of MorphoSys, as well as the Board of Directors of Constellation and is expected to close in the third quarter of 2021. MorphoSys also announced that it has entered into a long-term strategic fund
Royalty Pharma to provide tailored funding solution to enable MorphoSys' acquisition of Constellation PharmaceuticalsInvestment is anchored by royalties on Janssen's TremfyaPartnership also includes royalties on four development-stage therapies, Development Funding Bonds and an investment in MorphoSys common stockRoyalty Pharma to host conference call today, Wednesday, June 2 at 8:45am EDT NEW YORK and PLANEGG, Germany, June 02, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) and MorphoSys AG ((FSE: MOR, NASDAQ:MOR) today announced a $2.025 billion strategic funding partnership as part of MorphoSys' $1.7 billion acquisition of Constellation Pharmaceuticals (NASDAQ:CNST). This pa
Accelerates Growth Strategy by Adding Two Mid- to Late-Stage Product Candidates: Pelabresib (CPI-0610) and CPI-0209 Bolsters Position in Hematology-Oncology and Expands into Solid Tumors Best-in-Class Combined Discovery and Development Capabilities Accelerates Ability to Provide New Cancer Treatments to Patients MorphoSys Enters into Strategic Funding Partnership with Royalty Pharma MorphoSys to Host Conference Call and Webcast at 2:00 PM CEST / 8:00 AM EST Today MorphoSys AG ((FSE: MOR, NASDAQ:MOR) ("MorphoSys"), and Constellation Pharmaceuticals, Inc., (NASDAQ:CNST) ("Constellation") today announced that they have entered into a definitive agreement whereby MorphoSys will acquire Con
CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced the appointment of Brendan Delaney to the newly created position of Chief Commercial Officer, effective January 11, 2021. In this role, Mr. Delaney will be responsible for building and leading the Company’s commercial organization and pre-launch preparations in support of CPI-0610, which has the potential to be a disease-modifying therapy for patients living with myelofibrosis. “Brendan is joining Constellation at a pivotal time, and I look forward to working with him to advance the treatment paradigm for patients with myelofibrosis,” said Jigar Raythatha, President and C
SC 13G/A - CONSTELLATION PHARMACEUTICALS INC (0001434418) (Subject)
SC 13G/A - CONSTELLATION PHARMACEUTICALS INC (0001434418) (Subject)
SC 13G/A - CONSTELLATION PHARMACEUTICALS INC (0001434418) (Subject)